Study to Evaluate Three Times Per Week (TIW) Oral Dosing of Vadadustat for Anemia in Subjects With Dialysis-Dependent Chronic Kidney Disease (DD-CKD)

Inclusion Criteria: * Male and female subjects ≥18 years of age * Receiving chronic maintenance in-center hemodialysis (3 times per week) for end-stage kidney disease * Currently maintained on ESA therapy * Mean screening Hb between 8.0 and 11.0 g/dL (inclusive) Exclusion Criteria: * Anemia due to a cause other than CKD or presence of active bleeding or recent blood loss * Sickle cell disease, myelodysplastic syndromes, bone marrow fibrosis, hematologic malignancy, myeloma, hemolytic anemia, thalassemia, or pure red cell aplasia * Red blood cell transfusion within 4 weeks prior to or during screening * Anticipated to recover adequate kidney function to no longer require hemodialysis during study participation